InsidersTradesSigma
REGENXBIO Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the REGENXBIO Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, REGENXBIO Inc. has logged 124 reports. Market capitalisation: €721.2m. The latest transaction was disclosed on 6 July 2026 (Levée d'options). Among the most active insiders: Mills Kenneth T.. All data is openly available.
124
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€5m
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate REGENXBIO Inc. Buy (bullish), based on 11 analysts. Average price target: US$24.36.
39Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 21,641 of 26,212 companies
28.7
score / 100
Value10
Quality47
FCF yld-18%
Earn yld-27%
EV/EBITDA·
ROE-196%
Gross mgn88%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 6 July 2026
Declarations124 total
2,161 shares@ US$7.860.0022% mcap2.1% of flowCommon StockSEC:0001700659-26-000014:0
2,161 shares@ US$13.640.0039% mcap3.6% of flowCommon StockSEC:0001700659-26-000014:1
951 shares@ US$6.99551.0% of flowCommon StockSEC:0001346164-26-000006:0
1,453 shares@ US$10.180.0019% mcap2.3% of flowCommon StockSEC:0001346164-26-000006:1
6,818 shares@ US$13.090.012% mcap13.7% of flowCommon StockSEC:0001346164-26-000006:2
43,206 shares@ US$11.98CommonSEC144:0001950047-26-006719
9,807 shares0Common StockSEC:0001872219-26-000001:0
5,124 shares@ US$10.354.5% of flowCommon StockSEC:0001700659-26-000008:0
5,267 shares@ US$11.164.9% of flowCommon StockSEC:0001700659-26-000006:0
4,700 shares@ US$11.168.3% of flowCommon StockSEC:0001521123-26-000006:0
225,000 shares@ US$13.0965.9% of flowCommon StockSEC:0001652824-26-000002:0
73,749 shares0Common StockSEC:0001521123-26-000004:0
65,847 shares0Common StockSEC:0002062007-26-000003:0
73,749 shares0Common StockSEC:0001789335-26-000002:0
65,847 shares0Common StockSEC:0001700659-26-000004:0
144,864 shares0Common StockSEC:0001346164-26-000004:0
18,247 shares@ US$14.40Common StockSEC:0001700659-26-000003:0
9,793 shares@ US$14.40Common StockSEC:0001521123-26-000002:0
18,559 shares@ US$14.40Common StockSEC:0001346164-26-000002:0
1,238 shares@ US$14.4089.5% of flowCommon StockSEC:0002062007-26-000002:0
20,811 shares@ US$12.6224.5% of flowCommon StockSEC:0001346164-25-000005:0
7,624 shares@ US$10.039.3% of flowCommon StockSEC:0001346164-25-000003:0
7,734 shares@ US$10.0210.4% of flowCommon StockSEC:0001562180-25-006194:0
234 shares@ US$8.93100.0% of flowCommon StockSEC:0001562180-25-006079:0
4,901 shares@ US$8.93100.0% of flowCommon StockSEC:0001562180-25-006078:0
25 of 124 declarations
About REGENXBIO Inc.
REGENXBIO Inc. is a U.S.-based biotechnology company listed on the Nasdaq market in the United States, focused on in vivo gene therapy. Headquartered in Rockville, Maryland, the company develops treatments intended to address severe genetic and degenerative diseases, with a particular emphasis on rare diseases and retinal disorders. Its core competitive asset is its proprietary NAV Technology platform, designed to support AAV-based gene delivery and durable therapeutic expression. Founded in 2009, REGENXBIO has evolved into a recognized gene-therapy developer through a mix of internal R&D and strategic pharmaceutical partnerships. ([ir.regenxbio.com](https://ir.regenxbio.com/?utm_source=openai)) The company’s pipeline is centered on several clinical and pre-commercial programs. The most advanced asset is RGX-202, a gene therapy candidate for Duchenne muscular dystrophy. In 2025 and 2026, REGENXBIO reported encouraging interim data, completed pivotal enrollment, and began commercial production activities, with top-line pivotal data expected in early Q2 2026 and a BLA filing targeted for mid-2026. In rare lysosomal diseases, the company is developing RGX-121 for MPS II and RGX-111 for MPS I through a partnership with Nippon Shinyaku. In ophthalmology, REGENXBIO is advancing ABBV-RGX-314 with AbbVie for wet AMD and diabetic retinopathy. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates/?utm_source=openai)) From a commercial perspective, REGENXBIO is still largely a development-stage company, but its risk-reward profile has improved as its lead programs move closer to potential approval. Its competitive positioning is built on a combination of proprietary platform know-how, integrated manufacturing capabilities, and a pipeline aimed at high-unmet-need indications. The company manufactures RGX-202 at its Manufacturing Innovation Center in Rockville, which strengthens supply-chain control and could support future launch readiness. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates/?utm_source=openai)) Geographically, REGENXBIO remains primarily U.S.-anchored, with headquarters, research, and manufacturing operations in the United States, while its partnerships broaden potential commercialization into international markets. Agreements with AbbVie and Nippon Shinyaku extend the company’s reach and validate its technology platform. Recent highlights include continued positive data for RGX-202, ongoing regulatory progress for RGX-121, and manufacturing scale-up tied to a possible mid-2026 launch path. For European investors, this is a high-upside biotech name, but one that remains highly dependent on clinical execution, regulatory decisions, and eventual market adoption. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-reports-new-positive-interim-data-phase-iii-affinity/?utm_source=openai))
